鲁妥珠单抗
化合物
鲁妥珠单抗（INN：lumretuzumab；开发代号：RG7116），或译鲁姆妥珠单抗，是一种人源化抗HER3单克隆抗体，设计用于治疗癌症。[1][2]
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | HER3 |
| 临床资料 | |
| 其他名称 | RG7116 |
| ATC码 |
|
| 识别信息 | |
| CAS号 | 1448327-63-6 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6512H10064N1736O2052S44 |
| 摩尔质量 | 146,916.88 g·mol−1 |
一项Ib/II期研究调查了在第一线治疗晚期或转移性鳞状非小细胞肺癌（sqNSCLC）患者时，鲁妥珠单抗与卡铂和紫杉醇联合使用的安全性和临床活性。[3]
参考资料
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lumretuzumab, American Medical Association.
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 (PDF). WHO Drug Information. 2014, 28 (2).
- ^ Cejalvo, Juan-Miguel; Jacob, Wolfgang; Fleitas Kanonnikoff, Tania; Felip, Enriqueta; Navarro Mendivil, Alejandro; Martinez Garcia, Maria; Taus Garcia, Alvaro; Leighl, Natasha; Lassen, Ulrik; Mau-Soerensen, Morten; Adessi, Celine. A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. ESMO Open. 2019, 4 (4). doi:10.1136/esmoopen-2019-000532 （英语）.